Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates

Moderna Receives Health Canada Approval for Updated COVID-19 Vaccine Targeting SARS-CoV-2 Variant LP.8.1

3 days ago

All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone

Moderna to Present at Upcoming Conferences in September 2025

4 days ago

Moderna Reports Second Quarter 2025 Financial Results and Provides Business Updates

3 weeks ago

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13)

Updates 2025 projected revenue range to $1.5 to $2.2 billion, reflecting a $300 million reduction at the high end, primarily driven by timing of deliveries for contracted revenue into the first quarter of 2026

Improves 2025 expected GAAP operating expenses by approximately $400 million to a range of $5.9 to $6.1 billion

Reiterates 2025 expected year-end cash balance of approximately $6 billion

Announced three recent U.S. FDA approvals and positive Phase 3 efficacy results for seasonal influenza vaccine